{"entity":{"id":"nct05533697","kind":"trial","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Ipilimumab and Nivolumab in advanced solid tumours, run by ModernaTX, Inc., now recruiting.","summary":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05533697 by ModernaTX, Inc., with 361 participants planned, started 2022-09-01 and due to reach its primary completion in 2032-02-18. Interventions recorded: mRNA-4359, Pembrolizumab, Ipilimumab and Nivolumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05533697","url":"https://clinicaltrials.gov/study/NCT05533697"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","ipilimumab","nivolumab"],"companies":["moderna"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05533697","phase":"1/2","setting":"Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","sponsor":"ModernaTX, Inc.","participation":[{"nct":"NCT05533697","source":"https://clinicaltrials.gov/study/NCT05533697","fetchedAt":"2026-10-07T16:53:45.224Z","studySha256":"ab6ded0b06068c75600ce86c594cd28118b253f4ac3674bdd8977eb7ddb10d73","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-14","leadSponsor":"ModernaTX, Inc.","collaboratorCount":0,"minimumAge":"12 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":361,"enrolmentType":"ESTIMATED","siteCount":39,"recruitingSiteCount":35,"countries":["Australia","Germany","Italy","Poland","Spain","United Kingdom","United States"]}],"started":"2022-09-01","startedType":"actual","enrolled":361,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05533697/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/"}]}}